Diagnostic Performance of 99mTc-iPSMA SPECT/CT in the Initial Staging of Patients with Unfavorable Intermediate-, High-, and Very High-Risk Prostate Cancer: A Comparative Analysis with 18F-PSMA-1007 PET/CT
Authors:
- Joel E. Vargas-AhumadaJoel E. Vargas-Ahumada
- Sofía Denisse González-RuedaSofía Denisse González-Rueda
- Fabio Andrés Sinisterra-SolísFabio Andrés Sinisterra-Solís
- Pamela Casanova-TriviñoPamela Casanova-Triviño
- Quetzali Pitalúa-CortésQuetzali Pitalúa-Cortés
- Irma Soldevilla-GallardoIrma Soldevilla-Gallardo
- Anna ScavuzzoAnna Scavuzzo
- Miguel Angel Jimenez-RíosMiguel Angel Jimenez-Ríos
- Francisco Osvaldo García-PérezFrancisco Osvaldo García-Pérez
Open Access
Abstract
Prostate cancer is a leading cause of cancer death in men worldwide. Imaging plays a key role in disease detection and initial staging. Emerging data has shown the superiority of PSMA imaging with PET/CT over conventional imaging for primary diagnoses. Single photon emission computed tomography is more available worldwide, and the imaging agent is low in cost. The aim of this study is to compare the diagnostic accuracy of 99mTc-EDDA/HYNIC-iPSMA SPECT/CT to 18F-PSMA-1007 PET/CT in the primary diagnosis of prostate cancer and the impact on clinical staging. Methods: In this prospective controlled study, 18 patients with histologically confirmed prostate cancer with unfavorable intermediate-, high-, and very high-risk characteristics were recruited to undergo 18F-PSMA-PET/CT and 99mTc-iPSMA SPECT/CT. The median age of the patients was 71 years old, and the median PSA level was 23.3 ng/mL. Lesions were divided into the prostate, seminal vesicles, lymph nodes, bone, and visceral metastases. Volumetric analysis was also performed between the two imaging modalities and correlated with PSA levels. Results: A total of 257 lesions were detected on 18F-PSMA-PET/CT: prostate (n = 18), seminal vesicles (n = 12), locoregional lymph nodes (n = 62), non-locoregional (n = 67), bone (n = 90), and visceral (n = 8). Of these, 99mTc-iPSMA-SPECT/CT detected 229 lesions, while both reviewers detected 100% of the lesions in the prostate (18/18), seminal vesicles (12/12), and visceral (8/8); LN LR (56/62; 90%), NLR (57/67; 85%), and bone (78/90; 86%). There were no statistically significant differences between volumetric parameters (t = −0.02122; p = 0.491596). Conclusions: 99mTc-iPSMA SPECT/CT is useful in the primary diagnosis of prostate cancer. Despite it showing a slightly lower lesion detection rate compared to 18F-PSMA PET/CT, it exhibited no impact on clinical staging and, consequently, the initial treatment intention.Keywords
This publication has 33 references indexed in Scilit:
- Procedures for the GMP-Compliant Production and Quality Control of [18F]PSMA-1007—A Next Generation Radiofluorinated Tracer for the Detection of Prostate CancerPreprints.org, 2017
- The Diagnosis and Treatment of Prostate CancerJAMA, 2017
- Clinical translation of a PSMA inhibitor for 99m Tc-based SPECTNuclear Medicine and Biology, 2017
- Phase 2 Study of 99mTc-Trofolastat SPECT/CT to Identify and Localize Prostate Cancer in Intermediate- and High-Risk Patients Undergoing Radical Prostatectomy and Extended Pelvic LN DissectionJournal of Nuclear Medicine, 2017
- 18F-NaF-PET/CT and 99mTc-MDP Bone Scintigraphy in the Detection of Bone Metastases in Prostate CancerSeminars in Nuclear Medicine, 2016
- Diagnostic Efficacy of 68 Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate CancerJournal of Urology, 2016
- Current use of PSMA–PET in prostate cancer managementNature Reviews Urology, 2016
- The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.2006
- Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer.2003
- Prostate-specific membrane antigen expression in normal and malignant human tissues.1997